Article

Allergan enters patent battle over generic version of brimonidine tartrate solution

Irvine, CA-Allergan Inc. said it has filed a lawsuit against Alcon Laboratories Inc. claiming that the Fort Worth, TX company infringed upon Allergan's patents for brimonidine tartrate ophthalmic solution 0.15% to manufacture a generic alternative to its Alphagan P drops.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
Related Content
AI-assisted biomarker segmentation offers precision in nAMD disease monitoring
April 19th 2025

AI-assisted biomarker segmentation offers precision in nAMD disease monitoring

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs
April 18th 2025

50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

BVI Medical receives 510(k) FDA clearance for glaucoma surgical system
April 17th 2025

BVI Medical receives 510(k) FDA clearance for glaucoma surgical system

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
April 17th 2025

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA

© 2025 MJH Life Sciences

All rights reserved.